Want to see CUE full AI Analyst Report?
Cue Biopharma (CUE) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cue-102 | Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Gastric Cancer | Phase I | Completed | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Apr 19, 2022 | ― |
| Cue-101, Keytruda®, Pembrolizumab | Head And Neck Cancer, Hpv Positive Oropharyngeal Squamous Cell Carcinoma, Hpv-Related Carcinoma | Phase I | Active Not Recruiting | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | Jun 04, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cue-102 | Phase I | Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Gastric Cancer | Completed | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Apr 19, 2022 | ― |
| Cue-101, Keytruda®, Pembrolizumab | Phase I | Head And Neck Cancer, Hpv Positive Oropharyngeal Squamous Cell Carcinoma, Hpv-Related Carcinoma | Active Not Recruiting | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | Jun 04, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cue Biopharma (CUE) have in its pipeline
Cue Biopharma CUE is currently developing the following drugs: Cue-102, Cue-101, Keytruda®, Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.